From: Nonspecific interstitial pneumonia: clinical associations and outcomes
 | SAD-NSIP group | i-NSIP-Ab + group | i-NSIP-Ab-group |
---|---|---|---|
Initial therapy | Â | Â | Â |
 Prednisone, N (%) | 9/23(39.1) | 30/30(100) | 44/44(100) |
 Prednisone + immunosuppressive agent, N (%) | 14/23(60.9) | 0 | 0 |
Relapse, N (%) | 6/23(26.1) | 13/30(4.3) | 21/44(47.7) |
Emerging autoantibody, N (%) | 0 | 0 | 3/44(6.8) |
classifiable SAD, N (%) | 0 | 2/30(6.7) | 3/44(6.8) |
PAH, N (%) | 1/23(4.3) | 1/30(3.3) | 1/44(2.3) |
Lung infection, N (%) | 1/23(4.3) | 3/30(10.0) | 4/44(9.1) |
Death, N (%) | 8/23(34.8) | 8/30(26.7) | 9/44(20.5) |
 Underlying disease, N (%) | 4/23(17.4) | 6/30(20.0) | 6/44(13.6) |
 Lung infection, N (%) | 3/23(13.0) | 2/30(6.7) | 2/44(4.5) |
 Other, N (%) | 1/23(4.3) | 0 | 1/44(2.3) |